{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:48Z","timestamp":1790165208449,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016819","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106879","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:52:59Z","timestamp":1785253979000},"page":"106879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal before urgent surgery: subanalysis of the LEX-209 randomized, active-controlled trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-5158","authenticated-orcid":false,"given":"Ravi","family":"Sarode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Simonian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Hinterberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrii","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gareis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Truman J.","family":"Milling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106879_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106879_bib2","article-title":"Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.rpth.2026.106879_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20910855","article-title":"An update on the management of antiphospholipid syndrome","volume":"12","author":"Rodziewicz","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.rpth.2026.106879_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/asheducation-2008.1.266","article-title":"Management of excessive anticoagulant effect due to vitamin K antagonists","volume":"2008","author":"Dentali","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2026.106879_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.5694\/j.1326-5377.2000.tb124127.x","article-title":"Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis","volume":"172","author":"Gallus","year":"2000","journal-title":"Med J Aust"},{"key":"10.1016\/j.rpth.2026.106879_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2026.106879_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.106879_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/qjmed\/hcr136","article-title":"Risk factors of vitamin K antagonist overcoagulation","volume":"105","author":"Marie","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.rpth.2026.106879_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2025.104115","article-title":"Twenty years of the four-factor prothrombin complex concentrate Octaplex\/Balfaxar: a narrative review","volume":"64","author":"Karkouti","year":"2025","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.rpth.2026.106879_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24758","article-title":"Vitamin K antagonist reversal for urgent surgery using 4-factor prothrombin complex concentrates: a randomized clinical trial","volume":"7","author":"Sarode","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2026.106879_bib12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.106879_bib13","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106879_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2020.06.028","article-title":"Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal","volume":"194","author":"Makhoul","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106879_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.annemergmed.2015.04.036","article-title":"Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies","volume":"67","author":"Milling","year":"2016","journal-title":"Ann Emerg Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:22Z","timestamp":1790164222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035375"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106879","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal before urgent surgery: subanalysis of the LEX-209 randomized, active-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106879"}}